Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact
Seeking Low-Cost Practical Option For Sub-Saharan Africa
The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.
You may also be interested in...
The company has significantly built up its pipeline since divesting its oncology business to Servier, with multiple Phase III readouts for Pyrukynd expected in 2024-2025.
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.
Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.